{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:19:27Z","timestamp":1783430367342,"version":"3.54.6"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Emerging fluoroquinolone (FQ) resistance threatens multidrug-resistant tuberculosis (MDR-TB) management, complicating access to shorter regimens. This study characterizes FQ-resistant TB (FQ-R-TB) patients in Surabaya, Indonesia, and assesses diagnostic performance and therapeutic outcomes associated with this resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort analysis was conducted using national TB data from 1037 MDR-TB patients (2020\u20132025). Among them, 32 cases with genotypic FQ resistance (Xpert MTB\/XDR) were stratified into concordant (genotypic mutation with phenotypic resistance,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 21) and discordant (genotypic mutation with phenotypic susceptibility,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 11) groups. Demographics, comorbidities, diagnostics, and treatment outcomes were evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The proportion of FQ resistance among MDR-TB patients rose from 0% in 2020 to 1.37% in 2025. Discordant cases were significantly older (mean: 54 \u00b1 14;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.203), predominantly male (10:1;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.037), had higher body mass index (BMI; 24.44 \u00b1 6.04;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.197), and had a markedly higher prevalence of diabetes mellitus (90.9% versus 9.5%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.028). Diagnostic discordance occurred in 34.4% of FQ-R-TB cases, causing 1\u20133 month delays in regimen adjustment and initial ineffective FQ exposure. While subsequent FQ-free BPaL regimens improved outcomes, initial diagnostic uncertainty complicated decisions and increased adverse effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>FQ resistance is an emerging threat in Surabaya. Diagnostic discordance and high comorbidity burden complicate treatment. Advanced age and higher BMI are linked to increased diabetes probability. Diabetes is a powerful predictor of genotypic\u2013phenotypic discordance, likely via host-mediated mechanisms affecting bacterial fitness and resistance expression. A strong clinical consensus is needed to recommend genotypic test results as the primary guide for treating TB patients with diabetes. However, for diabetic TB patients whose initial phenotypic results indicate FQ susceptibility, close monitoring of their clinical and microbiological response during therapy remains crucial to confirm effectiveness until more definitive evidence is available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_70_26","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:17:09Z","timestamp":1782857829000},"page":"84-94","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Diabetes-associated Phenotypic Masking of Fluoroquinolone Resistance in Multidrug-resistant Tuberculosis: Evidence from Genotypic\u2013Phenotypic Discordance in Surabaya, Indonesia"],"prefix":"10.4103","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2528-2895","authenticated-orcid":false,"given":"Lyndia","family":"Effendy","sequence":"first","affiliation":[{"name":"Doctoral Program, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia"},{"name":"School of Medicine, Universitas Ciputra, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni Made","family":"Mertaniasih","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Parasitology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia"},{"name":"Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia"},{"name":"Departement of Central Laboratory, Universitas Airlangga Hospital, Surabaya, Indonesia"},{"name":"Departement of Clinical Microbiology, Dr. Soetomo Academic General Hospital, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7317-5619","authenticated-orcid":false,"given":"Soedarsono","family":"Soedarsono","sequence":"additional","affiliation":[{"name":"Sub Division of Pulmonology, Department of Internal Medicine, Faculty of Medicine, Universitas Hang Tuah, Surabaya, Indonesia"},{"name":"Department of Pulmonology and Respiratory Medicine, Dr. Soetomo Academic General Hospital, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tutik","family":"Kusmiati","sequence":"additional","affiliation":[{"name":"Department of Pulmonology and Respiratory Medicine, Dr. Soetomo Academic General Hospital, Surabaya, Indonesia"},{"name":"Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"R4-20260707","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40249-023-01107-x","article-title":"Global prevalence of drug-resistant tuberculosis: A systematic review and meta-analysis","volume":"12","author":"Salari","year":"2023","journal-title":"Infect Dis Poverty"},{"key":"R5-20260707","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3889\/oamjms.2022.8980","article-title":"Factors Associated of Multidrug-Resistance Tuberculosis among Minangkabau Ethnicity in Indonesia","volume":"10","author":"Kadri","year":"2022","journal-title":"Open Access Maced J Med Sci"},{"key":"R6-20260707","first-page":"6","article-title":"Investigating the types and mechanisms of Mycobacterium tuberculosis resistance: Why Indonesia continues to experience high case rates compared to other nations","author":"Siswanto","year":"2025","journal-title":"Curr Res Biosci Biotechnol"},{"issue":"Suppl 1","key":"R7-20260707","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.ijid.2022.03.026","article-title":"Drug resistant TB \u2013 Latest developments in epidemiology, diagnostics and management","volume":"124","author":"Tiberi","year":"2022","journal-title":"Int J Infect Dis"},{"key":"R8-20260707","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"R9-20260707","doi-asserted-by":"crossref","first-page":"101380","DOI":"10.1016\/j.lanepe.2025.101380","article-title":"Treatment outcomes of extensively drug-resistant tuberculosis in Europe: A retrospective cohort study","volume":"56","author":"Kherabi","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"R10-20260707","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S1473-3099(25)00362-7","article-title":"The patient pursuit of safe treatment options for tuberculosis","volume":"25","author":"Perumal","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"R11-20260707","first-page":"CD014841","article-title":"Xpert MTB\/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin","volume":"5","author":"Pillay","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"R12-20260707","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jgar.2023.05.001","article-title":"Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis","volume":"34","author":"An","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"R13-20260707","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/cid\/ciae560","article-title":"Population-level frequency of fluoroquinolone resistance by whole-genome sequencing drug predictions in Mycobacterium tuberculosis complex isolates in England from 2017 through 2023","volume":"80","author":"Ferran","year":"2025","journal-title":"Clin Infect Dis"},{"key":"R14-20260707","doi-asserted-by":"crossref","first-page":"938032","DOI":"10.3389\/fcimb.2022.938032","article-title":"Fluoroquinolone heteroresistance, antimicrobial tolerance, and lethality enhancement","volume":"12","author":"Singh","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"R15-20260707","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/14787210.2024.2400536","article-title":"Decoding drug resistance in Mycobacterium tuberculosis complex: Genetic insights and future challenges","volume":"22","author":"Deshpande","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R16-20260707","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): An open-label, multicentre, randomised, non-inferiority trial","volume":"400","author":"Goodall","year":"2022","journal-title":"Lancet"},{"key":"R17-20260707","first-page":"129","article-title":"Current understanding of Mycobacterium tuberculosis drug resistances and diagnostics in Indonesia: A review","volume":"4","author":"Rahayu","year":"2024","journal-title":"J Exp Clin Pharm"},{"key":"R18-20260707","doi-asserted-by":"crossref","first-page":"e0005275","DOI":"10.1371\/journal.pgph.0005275","article-title":"Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis","volume":"5","author":"Kim","year":"2025","journal-title":"PLOS Glob Public Health"},{"key":"R19-20260707","first-page":"404","article-title":"Association of Fluoroquinolone Resistance in Multi-drug Resistance Tuberculosis with Diabetes Mellitus: A Hospital-based Retrospective Study","volume":"6","author":"Vyas","year":"2024","journal-title":"Afr J Biol Sci"},{"key":"R20-20260707","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12879-022-07831-3","article-title":"Risk factors for multidrug resistance in tuberculosis patients with diabetes mellitus","volume":"22","author":"Li","year":"2022","journal-title":"BMC Infect Dis"},{"key":"R21-20260707","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/ijmy.ijmy_232_24","article-title":"Re-evaluated treatment outcomes of bacteriologically positive patients with tuberculosis registered at an urban health center, Lusaka, Zambia, 2023","volume":"14","author":"Daka","year":"2025","journal-title":"Int J Mycobacteriol"},{"key":"R22-20260707","first-page":"24","article-title":"Molecular identification of Aspergillus spp","volume":"14","author":"Asriany","year":"2025","journal-title":"in patients with clinical symptoms of tuberculosis. Int J Mycobacteriol"},{"key":"R23-20260707","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/ijmy.ijmy_99_25","article-title":"Molecular detection of Mycobacterium tuberculosis and nontuberculous Mycobacteria with drug resistance profiling using line probe assay in clinical samples from suspected tuberculosis patients in North Sumatra, Indonesia","volume":"14","author":"Kusumawati","year":"2025","journal-title":"Int J Mycobacteriol"},{"key":"R24-20260707","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4103\/ijmy.ijmy_151_25","article-title":"Agreement between TrueNat Mycobacterium tuberculosis\/rifampicin and microscopy for detection of pulmonary and extrapulmonary tuberculosis at a tertiary care Hospital of Eastern Uttar Pradesh, India","volume":"14","author":"Mohanty","year":"2025","journal-title":"Int J Mycobacteriol"},{"key":"R25-20260707","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1164\/rccm.202009-3527OC","article-title":"Evidence-based definition for extensively drug-resistant tuberculosis","volume":"204","author":"Roelens","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R26-20260707","doi-asserted-by":"crossref","first-page":"e0269765","DOI":"10.1371\/journal.pone.0269765","article-title":"Impact of adverse drug reactions on the outcomes of tuberculosis treatment","volume":"18","author":"Sant Anna","year":"2023","journal-title":"PLoS One"},{"key":"R27-20260707","doi-asserted-by":"crossref","first-page":"dlag007","DOI":"10.1093\/jacamr\/dlag007","article-title":"Within-host evolution of drug tolerance in Mycobacterium tuberculosis","volume":"8","author":"March","year":"2026","journal-title":"JAC Antimicrob Resist"},{"key":"R28-20260707","doi-asserted-by":"crossref","first-page":"fuaa071","DOI":"10.1093\/femsre\/fuaa071","article-title":"The within-host evolution of antimicrobial resistance in Mycobacterium tuberculosis","volume":"45","author":"Castro","year":"2021","journal-title":"FEMS Microbiol Rev"},{"key":"R29-20260707","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1111\/febs.17142","article-title":"Actionable mechanisms of drug tolerance and resistance in Mycobacterium tuberculosis","volume":"291","author":"Datta","year":"2024","journal-title":"FEBS J"},{"key":"R30-20260707","doi-asserted-by":"crossref","first-page":"e02266","DOI":"10.1128\/AAC.02266-17","article-title":"Extreme drug tolerance of Mycobacterium tuberculosis in Caseum","volume":"62","author":"Sarathy","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R32-20260707","doi-asserted-by":"crossref","first-page":"2534656","DOI":"10.1080\/22221751.2025.2534656","article-title":"Mixed infections and heteroresistance of Mycobacterium tuberculosis among multidrug-resistant tuberculosis in China: A genomic epidemiology study","volume":"14","author":"Liu","year":"2025","journal-title":"Emerg Microbes Infect"},{"key":"R33-20260707","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/cid\/cix556","article-title":"Fluoroquinolone resistance mutation detection is equivalent to culture-based drug sensitivity testing for Predicting multidrug-resistant tuberculosis treatment outcome: A retrospective cohort study","volume":"65","author":"Farhat","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R34-20260707","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12879-023-08130-1","article-title":"The differences in drug resistance between drug-resistant tuberculosis patients with and without diabetes mellitus in northeast China: A retrospective study","volume":"23","author":"Pan","year":"2023","journal-title":"BMC Infect Dis"},{"key":"R35-20260707","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1093\/cid\/ciz1179","article-title":"Clinical impact of rapid drug susceptibility testing to accompany fluoroquinolone-containing universal tuberculosis regimens: A Markov model","volume":"71","author":"Kendall","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijmy.ijmy_70_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:02:30Z","timestamp":1783429350000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.4103\/ijmy.ijmy_70_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_70_26","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2026-02-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}